{
    "organizations": [],
    "uuid": "38ebc5ae773b20458df582fa4171c44a85ecdbda",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bellus-health-inc-reports-qtrly-lo/brief-bellus-health-inc-reports-qtrly-loss-per-share-0-02-idUSASC0A2FZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Bellus Health Inc Reports Qtrly Loss Per Share $0.02",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - BELLUS Health Inc:\n* BELLUS HEALTH REPORTS FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018\n* BELLUS HEALTH INC QTRLY LOSS PER SHARE $0.02 * BELLUS HEALTH INC - EXPECTS TO SUBMIT CTA TO HEALTH CANADA IN Q2 OF 2018 TO INITIATE A PHASE 1 CLINICAL STUDY ON HUMANS IN Q3 OF 2018 FOR BLU-5937 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-16T04:30:00.000+03:00",
    "crawled": "2018-05-16T18:57:25.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "bellus",
        "health",
        "inc",
        "bellus",
        "health",
        "report",
        "financial",
        "operating",
        "result",
        "first",
        "quarter",
        "ended",
        "march",
        "bellus",
        "health",
        "inc",
        "qtrly",
        "loss",
        "per",
        "share",
        "bellus",
        "health",
        "inc",
        "expects",
        "submit",
        "cta",
        "health",
        "canada",
        "q2",
        "initiate",
        "phase",
        "clinical",
        "study",
        "human",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}